Reata Pharmaceuticals - RETA Stock Forecast, Price & News

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Analysts Set New Price Targets

RETA has been the subject of several research reports. LADENBURG THALM/SH SH reduced their price objective on Reata Pharmaceuticals from $75.00 to $67.00 in a report on Wednesday, May 11th. Robert W. Baird dropped their price target on Reata Pharmaceuticals from $37.00 to $27.00 and set a "neutral" rating for the company in a research report on Tuesday, August 9th. Citigroup raised their price target on Reata Pharmaceuticals from $43.00 to $46.00 and gave the stock a "buy" rating in a research report on Friday, May 27th. Finally, The Goldman Sachs Group dropped their price target on Reata Pharmaceuticals from $93.00 to $73.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Reata Pharmaceuticals has a consensus rating of "Hold" and an average price target of $57.57.

Reata Pharmaceuticals Price Performance

Shares of NASDAQ:RETA traded up $0.06 during midday trading on Friday, reaching $21.02. The company's stock had a trading volume of 733,015 shares, compared to its average volume of 627,780. Reata Pharmaceuticals has a 1 year low of $20.24 and a 1 year high of $116.04. The business has a 50 day moving average price of $31.65 and a 200 day moving average price of $30.40.

Reata Pharmaceuticals (NASDAQ:RETA - Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.90) by ($0.12). Reata Pharmaceuticals had a negative net margin of 3,045.98% and a negative return on equity of 190.87%. The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $1.46 million. During the same period last year, the firm posted ($2.00) EPS. Reata Pharmaceuticals's revenue was down 65.7% on a year-over-year basis. Equities research analysts forecast that Reata Pharmaceuticals will post -8.27 EPS for the current year.